Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada
Real-world data from the Canadian population suggest a low level of long-term persistence on selexipag, although the level of persistence is similar to reported rates for other PAH therapies. Further research into predictors of selexipag persistence is needed to help optimize potential treatment outcomes.
Authors
- Brad Millson (ORCID: https://orcid.org/0000-0002-3922-7072)
- Jason Weatherald (ORCID: https://orcid.org/0000-0002-0615-4575)
- Steeve Provencher (ORCID: https://orcid.org/0000-0001-7535-9972)
- Shane Golden
- Cindy Ying Yin Yip
- Jean‐Claude Mamputu (ORCID: https://orcid.org/0000-0001-8493-959X)
- Matthew Badin
- Chang Zhang (ORCID: https://orcid.org/0000-0002-4324-8909)
- John R. Swiston
- Jillian Murray
- Lisa Mielniczuk
Institutions
- Johnson & Johnson (United States) (US)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Alberta (CA)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
Publication Details
- Journal
- CJC Open
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.cjco.2025.10.009
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00